AzTrials
AzTrials

COPDPROMETENCT02499068

Madrid Project on the Management of Chronic Obstructive Pulmonary Disease With Home Telemonitoring

A study testing Telehealth in people with COPD and Disease Progression, run by Arturo Garcia at 5 sites in Spain.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of the study is to verify the clinical effectiveness of a managed home telemonitoring program in patients with severe COPD against usual clinical practice, as measured by the decrease in the number of exacerbations, number of hospitalizations, hospital days and emergency room visits in a 12 month period… Read more about this study

Who is it for?
Ages 50 to 90 years
Conditions the study is for
COPD, Disease Progression
What is being tested?
Telehealth
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
237 participants
Where
5 sitesSpain
Study dates
Dec 2013to 1 Jun 2016
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 50 to 90 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Being over 50 and under 90 years of age.
  • Being diagnosed with COPD according to the criteria of GesEPOC, with severe airflow obstruction defined as a forced expiratory volume in one second (FEV1) less than 50% of theoretical.
  • "Exacerbator phenotype" defined as COPD patients having two or more moderate or severe exacerbations per year (GesEPOC guide). These exacerbations should be separated by at least 4 weeks after the end of previous treatment or 6 weeks from the start in cases that have not been treated
  • Clinically stable condition, defined as 6 weeks without clinical symptoms since the last exacerbation of COPD.
  • Having home oxygen therapy.
  • Sign the informed consent.

Who cannot join

  • Inability of the patient or caregiver to understand the procedure of Telehealth program.
  • Have a life expectancy of less than one year.
  • Have terminal heart failure (NYHA functional class III-IV).
  • Having advanced renal insufficiency (creatinine clearance <30%) or be on dialysis program.
  • Have liver cirrhosis or be included in a program of liver transplantation.
  • Be institutionalized or in Residential hospice care.
Show all 9Show fewer
  • Having a mini-mental test-score less than 24, because this score suggests dementia
  • To be considered by your doctor as not comply the treatment or monitoring required by their lung disease.
  • Failure to meet any of the inclusion criteria.

Trial locations and contacts

5 sites in 1 country.

5 sites in 1 country

Spain5 sites
  • Hospital Universitario La Princesa

    Madrid, 28006

  • Hospital Universitario Fundación Jiménez Díaz

    Madrid, 28040

  • Hospital Universitario 12 de Octubre

    Madrid, 28041

  • Hospital Universitario La Paz

    Madrid, 28046

  • Hospital Universitario Rey Juan Carlos

    Madrid, 28933

Other trials in Spain

About this study

Official title: Proyecto Madrileño Sobre el Manejo de la Enfermedad Pulmonar Obstructiva Crónica Con Telemonitorización a Domicilio. (Multicentre Project on the Home Telemonitoring of Patients With Severe Chronic Obstructive Pulmonary Disease).

The purpose of the study is to verify the clinical effectiveness of a managed home telemonitoring program in patients with severe COPD against usual clinical practice, as measured by the decrease in the number of exacerbations, number of hospitalizations, hospital days and emergency room visits in a 12 month period

The primary endpoint of effectiveness is "severe exacerbations avoided."

The main hypothesis is that patients with severe or very severe COPD patients managed with a home telehealth program have better outcomes than patients managed according to usual clinical practice.

Read the detailed description

Randomized, controlled, multicenter, performance, cost assessment and economic evaluation clinical trial. An arm of the trial will consist of patients assigned to the intervention group (telehealth group: TG ), and the other arm will consist of patients randomized to the control group (routine clinical practice: RCP).

For the economic evaluation, the perspective of the health system will be used. Therefore it only direct costs will be considered. In the TG arm also intervention costs it will be considered.

Patient selection:

Responsible researcher at each hospital center will coordinate the patient selection process. The researchers will identify candidate patients screening through hospital medical records.

After this first screening, patients will be contacted and invited to participate in the study. In a personal interview, the researcher explains the study to the patient and deliver the information sheet, verifying that patient meets all inclusion/exclusion criteria, obtains informed consent and then proceeds to patient randomization. To avoid bias from exclusions, researchers will hold record with patient exclusion causes.

Every hospital centers will include on average 60 patients (30 in each arm). The inclusion of patients will be competitive; having centers including patients in the study until reaching the final sample size of 120 patients per arm.

Randomization:

To avoid selection bias, patients assigned to each group will be randomized. To ensure that the number of subjects in each arm is the same, a restrictive block randomization is performed. Randomization is performed using random number generation by computer and the block size of 10 units.

Home Telehealth program:

Vital sign devices being used: spirometer, pulse oximeter with capacity for heart rate monitor, blood pressure, Visionox® (device capable of measuring respiratory rate, compliance with the hours of oxygen, and the flow and pattern of oxygen used).

Devices send data automatically to a modem by Bluetooth. Modem receives and transmits data simultaneously from the monitoring devices to a Central Monitoring Center (CMC). Data received by the modem are encrypted and sent to the telehealth monitoring platform via a 3G signal.

The CMC is manned by registered nurses and operates during office hours, 7 days a week.

Nurses will attend the patient's home for: the installation of the telehealth devices; to perform a thorough training of the patients / caregivers in the use of equipment and the COPD telehealth program.

Patients will perform daily vital sign measurements at the same time, at rest, after administration of the medication and the pattern of oxygen used. Visionox® performs measurements of respiratory rate and oxygen adherence automatically.

Measured data will be monitored on a daily bases by the nurses at the CMC. CMC will follow-up information, filter for fle positives and false negatives, and use an application acting as a traffic light system:

  • Green: meant that measurements had been taken and were within the predefined limits, and no further action was required.
  • Yellow: "technical alert". This means that the measurements had not been taken or had not been received. This alert could lead to a "clinical alert" due to a lack of adherence or discouragement. When the parameters were not received the nurse at the CMC called the patient to find the reason behind the alert, and either ruled out medical causes or, if one, notified the researcher leading the study.
  • Red: "clinical alert". Meant that a measurement exceeded the limits that were previously preestablished for each.

Classification of severity of clinical alerts is performed by the CMC according to an algorithm. Depending n severity different early medical interventions are taken, or escalated to clinical responsible for early intervention.

Being tested
Telehealth
Medical subject headings
Pulmonary Disease, Chronic Obstructive, Disease Progression

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • TelehealthDevice

    Also called Telemedicine

    Monitoring devices installed at patients home and patients are monitored on a daily bases for early detection of exacerbations and prompt clinical intervention.and being follow-up on a daily bases for early detection and prompt intervention.

Study groups in NCT02499068
Study groupRoleWhat they receive
COPD, TelehealthExperimentalPatients randomized to this arm would be followed by home telehealth devices and monitored on a daily bases for early detection of exacerbations and prompt clinical intervention.
Receives: Device: Telehealth
COPD, Normal clinical practiceNo interventionPatients would do the usual clinical practice.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of hospitalizations due to exacerbation of COPD avoided

    Measured: 1 year

Secondary outcomes (3)
  1. Cost-efficiency of treatment

    Measured: 1 year

  2. Cost-utility of treatment

    Measured: 1 year

  3. satisfaction of both patients and clinician responsibility questionnaire

    Measured: 1 year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 Jul 2015 (estimated)
  2. Study startDec 2013
  3. Primary completion1 Jun 2016
  4. Study completion1 Jun 2016

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
237 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02499068
Sponsor's protocol ID
PROMETE
Acronym
PROMETE
Status last verified
Aug 2019
First submitted
20 Mar 2015
Last updated
6 Aug 2019
Results posted
No
Data monitoring committee
Yes

Publications

  • Segrelles Calvo G, Gomez-Suarez C, Soriano JB, Zamora E, Gonzalez-Gamarra A, Gonzalez-Bejar M, Jordan A, Tadeo E, Sebastian A, Fernandez G, Ancochea J. A home telehealth program for patients with severe COPD: the PROMETE study. Respir Med. 2014 Mar;108(3):453-62. doi: 10.1016/j.rmed.2013.12.003. Epub 2013 Dec 16.

    PubMed 24433744
  • Ancochea J, Garcia-Rio F, Vazquez-Espinosa E, Hernando-Sanz A, Lopez-Yepes L, Galera-Martinez R, Peces-Barba G, Perez-Warnisher MT, Segrelles-Calvo G, Zamarro C, Gonzalez-Ponce P, Ramos MI, Conforto JI, Jafri S, Soriano JB. Efficacy and costs of telehealth for the management of COPD: the PROMETE II trial. Eur Respir J. 2018 May 30;51(5):1800354. doi: 10.1183/13993003.00354-2018. Print 2018 May. No abstract available.

    PubMed 29599185

Questions about this trial

What is this clinical trial studying?

A study testing Telehealth in people with COPD and Disease Progression, run by Arturo Garcia at 5 sites in Spain.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 6 Aug 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 5 sites in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of hospitalizations due to exacerbation of COPD avoided (time frame: 1 year). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02499068, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Aug 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in